News Alerts

08 Jan 2020 | 06:40 AM UTC

Fiji: Officials confirm 27 measles cases in Central Division January 3 /update 1

Fiji News Alert

Health officials in Fiji confirm 27 measles cases in Central Division as of January 3; take necessary precautions

TIMEFRAME expected from 1/8/2020, 12:00 AM until 2/8/2020, 11:59 PM (Pacific/Fiji). COUNTRY/REGION Fiji

Read all related news alert(s):

Event

The Fiji Ministry of Health and Medical Services has confirmed 27 cases of measles in the Central division as of Friday, January 3. Cases are being reported in the Serua/Namosi, Suva, Rewa and Naitasiri subdivisions. Health officials announced that the national vaccination campaign resumed on Monday, January 6 (having been suspended temporarily during Tropical Cyclone Sarai). Approximately 328,000 people have been vaccinated since the outbreak was declared on November 7, 2019.

Further spread of the disease is possible over the coming weeks.

Context

Measles is a highly contagious viral disease that typically affects mostly children. It is transmitted via droplets from the nose, mouth, or throat of infected persons. Symptoms of measles are usually a high fever, which begins approximately ten to 12 days after exposure to the virus and lasts four to seven days. A runny nose, a cough, red and watery eyes, and small white spots inside the cheeks can develop in the initial stage. After several days, a rash erupts, usually on the face and upper neck. Over the course of about three days, the rash spreads, eventually reaching the hands and feet. The rash lasts for five to six days and then fades. On average, the rash occurs 14 days after exposure to the virus (within a range of seven to 18 days). A vaccine is available.

Advice

Individuals in Fiji are advised to ensure their measles vaccination is up to date (including booster shots) and to contact their doctor with any questions or concerns. Anyone experiencing the above symptoms is urged to seek immediate medical attention.

 

Copyright and Disclaimer
GardaWorld is the owner or licensee of all intellectual property rights in the material presented on this website. All such rights are reserved. The use of this website and its material is subject to the Terms of Use and accordingly you must not use any content from this website for commercial or other analogous purposes without our consent, including but not limited to any deep-linking or framing in order to copy, distribute, display or monitor any portion of the website. If you have any questions or are interested in distributing any content from this website, Contact us for more details.

Related news